George Somlo Selected Research

Neoadjuvant Therapy

1/2023	Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
1/2022	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
1/2021	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
1/2019	Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.
1/2018	Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis.
11/2016	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
9/2015	Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
2/2015	Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
1/2015	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
6/2013	Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Somlo Research Topics

Disease

67	Neoplasms (Cancer) 01/2022 - 11/2002
66	Breast Neoplasms (Breast Cancer) 01/2023 - 06/2002
26	Multiple Myeloma 05/2024 - 11/2003
10	Triple Negative Breast Neoplasms 09/2023 - 01/2015
6	Disease Progression 09/2023 - 12/2011
6	Pathologic Complete Response 01/2023 - 06/2013
6	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2007
5	Leukemia 01/2022 - 02/2003
4	Circulating Neoplastic Cells 01/2022 - 09/2009
4	Peripheral Nervous System Diseases (PNS Diseases) 10/2012 - 01/2004
3	Nausea 08/2017 - 02/2007
3	Thrombocytopenia (Thrombopenia) 08/2017 - 02/2003
3	Lymphoma (Lymphomas) 10/2015 - 05/2005
3	Infections 01/2015 - 07/2006
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2013 - 02/2003
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2013 - 05/2008
3	Sarcoma (Soft Tissue Sarcoma) 08/2010 - 09/2004
2	Residual Neoplasm 05/2024 - 01/2021
2	Carcinogenesis 01/2020 - 01/2013
2	Inflammatory Breast Neoplasms 01/2018 - 05/2004
2	Fatigue 08/2015 - 09/2007
2	Bronchiolitis Obliterans Syndrome 08/2014 - 04/2005
2	Lung Neoplasms (Lung Cancer) 01/2013 - 09/2009
2	Vomiting 07/2012 - 02/2007

Drug/Important Bio-Agent (IBA)

10	Hormones (Hormone)IBA 09/2022 - 04/2013
10	Estrogen ReceptorsIBA 12/2021 - 05/2004
9	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 10/2004
9	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2008
8	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2023 - 01/2004
7	Bortezomib (Velcade)FDA Link 03/2024 - 01/2009
7	Trastuzumab (Herceptin)FDA Link 01/2023 - 03/2006
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2004
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2004
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2005
7	MicroRNAs (MicroRNA)IBA 02/2016 - 08/2009
5	Lenalidomide (CC 5013)FDA Link 05/2024 - 02/2013
5	Melphalan (Alkeran)FDA LinkGeneric 03/2024 - 01/2009
5	130-nm albumin-bound paclitaxelIBA 01/2023 - 01/2015
5	PlatinumIBA 01/2022 - 11/2002
5	Bevacizumab (Avastin)FDA Link 01/2022 - 08/2011
5	Dexamethasone (Maxidex)FDA LinkGeneric 11/2021 - 03/2012
5	Gemcitabine FDA Link 01/2010 - 11/2002
4	human ERBB2 proteinIBA 01/2023 - 08/2010
4	ErbB Receptors (EGF Receptor)IBA 09/2022 - 09/2009
4	RNA (Ribonucleic Acid)IBA 12/2021 - 03/2012
4	Interleukin-6 (Interleukin 6)IBA 10/2017 - 12/2010
3	fludarabineIBA 03/2024 - 01/2009
3	AnthracyclinesIBA 09/2023 - 07/2012
3	Aromatase InhibitorsIBA 09/2022 - 03/2006
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2005
3	Estrogens (Estrogen)FDA Link 12/2021 - 07/2011
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 01/2018
3	Docetaxel (Taxotere)FDA Link 01/2018 - 12/2003
3	Monoclonal AntibodiesIBA 11/2015 - 12/2009
3	CytokinesIBA 08/2015 - 06/2012
3	Progesterone Receptors (Progesterone Receptor)IBA 04/2014 - 05/2004
3	carfilzomibIBA 10/2012 - 06/2011
3	Thalidomide (Thalomid)FDA Link 03/2012 - 09/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2009 - 01/2005
3	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 01/2009 - 01/2005
2	Immune Checkpoint InhibitorsIBA 09/2023 - 09/2022
2	pembrolizumabIBA 09/2023 - 09/2022
2	Everolimus FDA Link 01/2022 - 08/2018
2	Etoposide (VP 16)FDA LinkGeneric 01/2022 - 11/2005
2	pomalidomideIBA 11/2021 - 07/2018
2	LeptinIBA 01/2020 - 01/2018
2	palbociclibIBA 04/2019 - 06/2018
2	sapanisertibIBA 04/2019 - 08/2018
2	Phosphotransferases (Kinase)IBA 04/2019 - 12/2010
2	trans-crotonin (CTN)IBA 01/2019 - 12/2011
2	Vorinostat FDA Link 01/2018 - 11/2008
2	fibrin fragment D (D-dimer)IBA 10/2017 - 08/2017
2	Blood Coagulation Factors (Coagulation Factor)IBA 10/2017 - 08/2017
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2017 - 11/2014
2	veliparibIBA 08/2017 - 11/2014
2	Phenobarbital (Luminal)FDA Link 01/2017 - 01/2013
2	Filgrastim (Neupogen)FDA Link 10/2015 - 01/2014
2	taxaneIBA 02/2015 - 01/2014
2	DNA (Deoxyribonucleic Acid)IBA 11/2014 - 09/2009
2	Vinorelbine (Navelbine)FDA LinkGeneric 04/2014 - 01/2014
2	Dasatinib (BMS 354825)FDA Link 06/2013 - 04/2013
2	Capecitabine (Xeloda)FDA Link 04/2013 - 11/2009
2	Proteasome InhibitorsIBA 10/2012 - 10/2012

Therapy/Procedure

42	Therapeutics 10/2022 - 11/2003
32	Drug Therapy (Chemotherapy) 09/2023 - 06/2003
12	Neoadjuvant Therapy 01/2023 - 01/2012
10	Cell Transplantation 05/2024 - 11/2003
8	Stem Cell Transplantation 08/2014 - 02/2003
6	Adjuvant Chemotherapy 12/2018 - 09/2009
6	Radiotherapy 01/2017 - 05/2004
4	Transplantation 01/2019 - 06/2003
3	Autologous Transplantation 01/2022 - 08/2009
3	Biological Therapy 03/2016 - 04/2014
3	Homologous Transplantation 01/2013 - 02/2003
3	Salvage Therapy 01/2013 - 04/2005
2	Aftercare (After-Treatment) 01/2018 - 09/2009
2	Immunotherapy 01/2018 - 02/2003
2	Segmental Mastectomy (Lumpectomy) 01/2016 - 09/2015
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 03/2012 - 11/2005
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2011 - 01/2009